In vitro 24-hour time-kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 10, 2009, Pages 4495-4497

  Singh, Shveta Rani ^a   Bacon III, Alfred E ^a   Young, David C ^a   Couch, Kimberly A ^a  

^a CHRISTIANA CARE HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; METICILLIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BLOOD CULTURE; BROTH DILUTION; DRUG ANTAGONISM; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DRUG ANTAGONISM; DRUG SYNERGISM; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; VANCOMYCIN;

EID: 70349330330     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00237-09     Document Type: Article

References (18)

1. Barry, A. L., W. C. Craig, H. Nadler, L. B. Reller, C. C. Sanders, and J. M. Swenson. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. NCCLS document M26-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
2. Chiang, F. Y., and M. Climo. 2003. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47:3002-3004.
3. Deville, J. G., S. Adler, P. H. Azimi, B. A. Jantausch, M. R. Morfin, S. Beltran, B. Edge-Padbury, S. Naberhuis-Stehouwer, and J. B. Bruss. 2003. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr. Infect. Dis. J. 22(Suppl.): S158-S163.
4. Drinka, P. J., M. E. Stemper, C. D. Gauerke, J. E. Miller, B. M. Goodman, and K. D. Reed. 2005. Clustering of multiple endemic strains of methicillin-resistant Staphylococcus aureus in a nursing home: an 8-year study. Infect. Control Hosp. Epidemiol. 26:215-218.
5. Jacqueline, C., J. Callion, V. Le Mabecque, A. F. Miegeville, P. Y. Donnio, D. Bugnon, and G. Potel. 2003. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J. Antimicrob. Chemother. 51:857-864.
6. Jones, R. N., T. R. Anderegg, and L. M. Deshpande. 2002. AZD2563, a new oxazolidinone: bactericidal activity and synergy studies combined with gentamicin or vancomycin against staphylococci and streptococcal strains. Diagn. Microbiol. Infect. Dis. 43:87-90.
7. Kallen, A., T. Driscoll, S. Thorton, P. Olson, and M. Wallace. 2000. Increase in community-acquired methicillin-resistant Staphylococcus aureus at a Naval Medical Center. Infect. Control Hosp. Epidemiol. 21:223-226.
8. Kowalski, T. J., E. F. Berbari, and D. R. Osmon. 2005. Epidemiology, treatment, and prevention of community-acquired methicillin-resistant Staphylococcus aureus infections. Mayo Clin. Proc. 80:1201-1207.
9. Kreman, T., J. Hu, J. Pottinger, and L. A. Herwaldt. 2005. Survey of long-term-care facilities in Iowa for policies and practices regarding residents with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci. Infect. Control Hosp. Epidemiol. 26:811-815.
10. National Nosocomial Infections Surveillance System. 2004. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 32:470-485.
11. Samra, Z., O. Ofer, and H. Shmuely. 2005. Susceptibility of methicillin-resistant Staphylococcus aureus to vancomycin, teicoplanin, linezolid, pristinamycin and other antibiotics. Isr. Med. Assoc. J. 7:148-150.
12. Sweeney, M. T., and G. E. Zurenko. 2003. In vitro activity of linezolid combined with other antimicrobial agents against staphylococci, enterococci, pneumococci, and selected gram-negative organisms. Antimicrob. Agents Chemother. 47:1902-1906.
13. Swenson, J. M., J. B. Patel, and J. H. Jorgensen. 2007. Special phenotypic methods for detecting antibacterial resistance, p. 1173-1192. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.
14. Tenover, F. C., L. M. Weigel, P. C. Appelbaum, L. K. McDougal, J. Chaitram, S. McAllister, N. Clark, G. Killgore, C. M. O'Hara, L. Jevitt, J. B. Patel, and B. Bozdogan. 2004. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob. Agents Chemother. 48:275-280.
15. Weigelt, J., K. Itani, D. Stevens, W. Lau, M. Dryden, C. Knirsch, et al. 2005. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 49:2260-2266.
16. Weigelt, J., H. M. Kaafarani, K. M. Itani, and R. N. Swanson. 2004. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am. J. Surg. 188:760-766.
17. Wunderink, R. G., J. Rello, S. K. Cammarata, R. V. Croos-Dabrera, and M. H. Kollef. 2003. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124:1789-1797.
18. Zetola, N., J. S. Francis, E. L. Nuermberger, and W. R. Bishai. 2005. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect. Dis. 5:275-286.